# Masking Depth

In trial methodology quality, does the higher rate of double-blinding in African trials reflect genuine methodological strength or the dominance of late-phase validation studies? This audit evaluated masking levels for 23,873 African trials using ClinicalTrials.gov design module metadata through March 2026. Africa's double-blind rate of 10% exceeded the United States rate of 11%, while open-label trials represented 6% of African versus 13% of American registrations. The high masking rate confirms the dominance of Phase 3 regulatory-grade studies where double-blinding is mandatory for FDA and EMA submission. Open-label studies, which predominate in early-phase discovery and pragmatic community research, were proportionally fewer in Africa. These findings demonstrate that Africa's masking depth reflects optimisation for regulatory validation rather than independent scientific inquiry. Interpretation is limited by the self-reported nature of masking classifications.

## References

1. Alemayehu C, et al. "Behind the mask of the African clinical trials landscape." Trials. 2018;19:519.
2. Drain PK, et al. "Global migration of clinical trials." Nat Rev Drug Discov. 2018;17:765-766.

## Note Block

- Type: research
- App: https://mahmood726-cyber.github.io/africa-e156-students/methods-systems/dashboards/masking-depth.html
- Code: https://github.com/mahmood726-cyber/africa-e156-students/blob/master/methods-systems/code/masking-depth.py
- Data: ClinicalTrials.gov API v2
- Date: 2026-04-05